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A B S T R A C T
Objective of this paper is to review drug-induced movement disorders (D-IMD) treated patients on Department of
Neurology in University Hospital Osijek. We reviewed patients treated during 10 years period (from 1992 to 2002).
Analysed group consisted of 14 patients. Reasons for hospitalisation were swallowing problems in 6 patients, neu-
roleptic malignant syndrome (NMS) in 3 patients, stroke in 2 patients, bolus choking in 2 patients, and speech distur-
bance in 1 patient. Working diagnosis for most of our patients was neurological disease, yet only later D-IMD diagnosis
was established excluding primary neurological disease, or as associated disease to basic neurological disorder. Nine
patients have diagnosed as Parkinson syndrome, 3 patients as NMS, and 4 as orolingual dyskinesia, either autono-
mously, or in combination with Parkinson syndrome. D-IMD was most frequently caused by neuroleptics. Thus the
small number of patients hospitalised regarding this syndrome on Department of Neurology.
Key words: drug-induced movement disorders, Parkinson syndrome, orolingual dyskinesia, neuroleptic malignant
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Introduction
The objective of the paper is to study drug-induced
movement disorders (D-IMD) treated patients on De-
partment of Neurology in University Hospital Osijek
during a ten-year period in order to show possible clini-
cal manifestations of the syndrome and to investigate
the reasons for D-IMD patients’ hospitalization on De-
partment of Neurology, since most frequent D-IMD cau-
se is neuroleptic therapy, and therefore this disorder is
in the domain of Department of Psychiatry.
Drug-induced movement disorder is neurologic moto-
ric disturbance caused by drugs. Its features are: abnor-
mally increased motor activity, impaired back posture,
abnormally decreased motoric function, mobility and
posture. It may be persistent or reversible1. The most
common form is Parkinson syndrome, characterized by
bradykinesia, rigidity and tremor2. Tardive dyskinesia,
akathisia, ticks and dystonia may also be found as part
of the syndrome3,4,5. The most severe manifestation is
neuroleptic malignant syndrome (NMS) – characterized
by severe rigidity, akinesia, hyperthermia, autonomous
disturbances, and changes in serum: leukocytosis, ele-
vated sedimentation rate, increase of creatinin-phos-
phokinase and liver enzymes levels)3,4.
Simultaneous use of different neuroleptics, depot
drugs, concurrent lithium therapy, organic brain dam-
age, dehydration and excessive heat exposure and male
sex are higher risk factors for NMS3. In general, older,
as well as female patients, have more chances to de-
velop D-IMD. It is suspected that there is a hereditary
predisposition for D-IMD too6.
It is well known that many drugs may cause D-IMD,
but some of them are more often charged as guilty for
this syndrome. The most common cause of D-IMD is
neuroleptic therapy, more often typical neuroleptics in
comparison to atypical ones. However, levodopa prod-
ucts, drugs that empty dopamin pools, sedatives, cal-
cium channel blockers, MAO inhibitors, natrium channel
blockers, cytostatics, antimycotics, selective serotonin
reuptake inhibitors, cholinesterase inhibitors, lithium
carbonate and antiepileptics may cause this syndrome
as well7–11.
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Division to typical and atypicial neuroleptics is fo-
unded on several factors, among which the most impor-
tant is affinity toward dopamine D2 system. The affinity
toward dopamine D2 system is less prominent in atypi-
cal neuroleptics, causing smaller frequency of extra-
pyramidal side effects.
Duration of D-IMD causing therapy, as well as daily
neuroleptic doses aren’t correlated with appearance of
D-IMD6. It is considered that real cause of extrapyramid
symptoms is not only block of dopaminergic receptors,
but possible toxic basal ganglia effect is suspected12.
Some of these patients, especially those with NMS are
life endangered due to possible myocardial infarction,
aspiration pneumonia or rhabdomyoliysis with acute re-
nal insufficiency3. Therefore it is very important to sus-
pect and establish correct diagnosis in order to start
proper therapy on time and prevent letal outcome.
Therapeutic approach consists of terminating drugs
that are suspected to cause the syndrome, bearing in
mind higher risk of worsening symptoms of basic psy-
chiatric disease, use of anticholinergic drugs, and some-
times small doses of dopaminomimetic agents7.
Parkinson syndrome usually diminish after the ther-
apy, although, symptoms may persist in some patients
in spite of treatment. It is supposed that they had latent
or subclinic form of Parkinson disease which manifested
after the neuroleptics therapy13,14 due to additional ef-
fect on basal ganglia.
Materials and Methods
Patients treated on Department of Neurology in Uni-
versity Hospital Osijek which had diagnosis of drug-in-
duced movement disorders were analyzed during 10
years period (from year 1992 to 2002). University hospital
Osijek is regional hospital for the East Slavonia and
Baranja district. Our hospital covers population of 300,000
people, while the rest of East Slavonian population is
covered by general hospitals in Vukovar and Vinkovci.
All of our patients come from district of City of Osijek
and surroundings.
Disease data were retrieved from patients’ records on
basis of hospital treated patients index on Department
of Neurology. Patients were found in our index regard-
ing discharge letter diagnosis of D-IMD. All the in-hos-
pital patients met the criteria we’d set, and therefore
none of them were excluded from the study. Only dis-
charge letter from the Department of Neurology was re-
viewed per patient during the study period in order to
assess the necessary data. Follow-up timeframe was up
to patients discharge from the Department of Neurol-
ogy. Not a single of these patients had more than one
hospitalisation on the Department of neurology regard-
ing these disorders. Ambulatory checked and treated
patients weren’t included in the examination.
Diagnoses of drug-induced movement disorders were
made on basis of anamnestic data, neurologic and physi-
cal examination and laboratory findings.
Among anamnestic data we searched for suspected
drug-induced movement disorders therapy use and du-
ration of that kind of a treatment. Neurological exami-
nation revealed extrapyramid symptoms and signs such
as rigidity, bradykinesia, tremor and orolingual dyski-
nesia. Hyperpyrexia and autonomous disorders (blood
pressure and heart rate disorder) were found during the
physical examination. Laboratory findings revealed ele-
vated sedimentation rate, increase in leukocytes num-
ber, creatinin-phosphokinase and liver enzymes levels.
Reasons for D-IMS patients’ hospitalisation and clin-
ical manifestation of extrapyramide syndrome were an-
alyzed, as well as medicamentous therapy that patients
used and which could have caused this syndrome, and
time duration from beginning of therapy to extrapyra-
midal symptoms onset. We studied length of hospitali-
sation, disease therapy during hospitalisation, course of
disease and its final outcome.
Results
Examined group consisted of 14 patients; 8 of them
female, 6 male. Average age was 70, 74 in female group,
and 69.7 in male, in the range of 55 to 80 (female 55 to
80, male 64 to 75).
Reasons for hospitalisation were swallowing prob-
lems (6 patients), malignant neuroleptic syndrome (3
patients), cerebrovascular infarction (2 patients), bolus
choking (2 patients), and speech disturbance (1 patient).
In discharge letter 9 patients had diagnosed as Par-
kinson syndrome, 3 patients as NMS, and 4 as oro-
lingual dyskinesia, either autonomously, or in combina-
tion with Parkinson syndrome.
Used drugs analysis showed that D-IMD was most
frequently caused by neuroleptics; typical ones: flu-
fenazin and haloperidol used 7 patients, promazine 5
patients, and sulpirid used 1 patient; and atypical ones:
clozapin used 2 patients, and 1 patient used olanzapin.
Most patients, 5 of them, had monotherapy treatment, 4
patients used two neuroleptics simultaneously, and 4
patients used three kinds of neuroleptics at the same
time. Considering other groups of drugs, DIMD was also
caused by levodopa in 1 patient, and metoclopramid in 1
patient.
D-IMD presented with different symptoms: 9 pa-
tients had Parkinson syndrome, 3 patients had NMS,
and 4 patients had orolingual dyskinesia either autono-
mously, or in combination with Parkinson syndrome.
Time of duration of therapy untill symptom onset
ranged from 10 days to 22 years. 3 patients developed
symptoms in period from 0 to 1 year of drug usage, 5 pa-
tients in period of 2 to 10 years, and 3 patients in period
11 to 20 years, and 1 patient in period longer than 20
years. Data of duration of therapy usage before onset of
symptoms remained unknown for 2 patients.
During the hospitalisation patients were treated by
terminating incriminated drugs therapy, infusion, bipe-
ridin, levodopa products and sedatives.
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Basic psychiatric disease had worsened in 4 patients,
5 patients presented no changes in extrapyramidale
(EP) symptomatology, and decrease of EP symptoms
was noticed in 2 patients, while 3 patients fully recov-
ered. Average hospitalisation duration was 14.9 days, in
the range of 3 to 24 days. 11 patients were discharged
after the end of treatment, 2 patients were transferred
to other departments for further treatment, and 1 pa-
tient died.
Discussion
Although many drugs may cause extrapyramide side
effects, neuroleptics are the most often cause of D-IMD.
Thus the small number of patients hospitalised regard-
ing this syndrome on Department of Neurology. Work-
ing diagnosis for most of our patients was neurological
disease, yet only later D-IMD diagnosis was established
excluding primary neurological disease, or as associated
disease to basic neurological disorder. Patients with
cerebrovascular infarction had reason for hospitaliza-
tion on our Department. Later on, during their stay on
our department we found out that they also have had
the symptoms of drug-induced movement disorders (not
related to CVI). Patients with neuroleptic malignant
syndrome were hospitalised due to life threatening state
and it's emergency on Department of Neurology.
During the almost same time interval (year 1993 to
2002) 45 patients were hospitalised on Department of
Psychiatry University Hospital Osijek with D-IMD di-
agnosis5.
D-IMD is more often correlated with typical neuro-
leptics use during psychiatric disorders treatment5,15–18.
Some authors found 30% prevalence of tardive dyskinesia
in psychiatric patients using neuroleptics20, while other
authors published frequency of 40.6% and 29%2,17–19.
Most of our patients had typical neuroleptics in their
therapy protocol. Therapy protocol analysis showerd
that majority of them had two or three neuroleptics at
the same time, while only fewer number of patients
were on monotherapy. In case patient had been using
just one drug in its therapy, the anamnestic data ex-
posed potential movement disorder causing drug. Oth-
erwise, if more than one neuroleptic was included in pa-
tient’s treatment, it was impossible to assert the right
drug that induced the movement disorder.
It is considered that D-IMD begins as a result of D2
receptor block. However, besides D2 receptors effect,
some authors believe that D-IMD develops due to me-
dicamentous toxic effect on basal ganglia12,21. Thus the
maintenance of Parkinson syndrome after termination
of D-IMD inducing therapy can be explained. Some au-
thors proved correlation between tardive dyskinesia on-
set and genetic precondition7,22,23.
D-IMD is one of many factors that should influence
therapy choice in psychiatric patients. Atypical neu-
roleptics are generally preferred to typical ones due to
less extrapyramidal symptoms coincidence, as well as
antidyskinetic effects in patients with tardive dyski-
nesia18,24,25.
Pisa syndrome (rare type of truncal dystonia), sort of
D-IMD presentation, develops more often in patients
whom had an additional neuroleptic therapy introdu-
ced, or patients with increased dosage of neuroleptic4.
Some authors find correlation between daily neuroleptic
dose or depot neuroleptic product use and tardive dys-
kinesia26, while other authors deny such correlation7.
Our data showed that older patients are more prone
to development of D-IMD, which is confirmed by other
authors7,15,17,26. We haven’t been able to analyze neither
frequency, nor statistical importance of this disorder
considering sex due to small number of patients in our
review, although some authors showed not only correla-
tion between DIMD and age and organic injury, but to
female sex as well4,7.
Most of our patients developed D-IMD after 2 to 10
years of therapy. The same number of patients used
therapy less than one year; and more than 11 years, yet
less than 20 years. Hall et al. didn’t find correlation be-
tween therapy duration and D-IMD6.
During hospitalization our patients were treated
with anticholinergic agents (biperidine), the ones other
authors found successful in D-IMD treatment too4,5,18,20.
Drugs caused dystonia diminished after anticholinergic
agent therapy only in 40% of cases, while the same ther-
apy showed better results in cases of symptoms of idiopa-
thic dystoniae4. We also used infusion, levodopa prod-
ucts and sedatives, while D-IMD inducing drugs therapy
was terminated. In some cases clozapin was proved as
successful therapy in tardive dyskinesia treatment24.
Effect of donezepil, a cholinesterase inhibitor, used in
dementia treatment is being studied27.
Current D-IMD therapy model results are still un-
satisfactory. It is noticed that there are always differ-
ences in therapy response between two different clinical
D-IMD manifestations. Reports show that tardive dys-
kinesia is much less responsive to therapy than dys-
tonia4.
Most of our patients showed progression of psychiat-
ric symptoms, or no regression of extrapyramidal symp-
toms at all, during the treatment. Only less number of
patients fully recovered, or showed decrease of D-IMD
symptoms. One third of patients had dyskinesiae even
one year after ending of neuroleptic therapy28. Tardive
dyskinesia treatment discouraging, therefore it empha-
sizes prevention of this syndrome by carefully choosing
atypical neuroleptic29, or, switching from typical to atyp-
ical neuroleptics in case of already developed extra-
pyramidal symptoms30.
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PRIKAZ PACIJENATA: JATROGENI EKSTRAPIRAMIDNI SINDROM
S A @ E T A K
Cilj rada bio je prikazati bolesnike lije~ene od jatrogenog ekstrapiramidnog sindroma (D-IMD) na Klinici za neuro-
logiju Klini~ke bolnice Osijek. Prikazali smo bolesnike lije~ene u periodu od 10 godina (od 1992–2002. god.). U ana-
liziranoj skupini je bilo 14 bolesnika. Razlozi za hospitalizaciju bili su u 6 bolesnika smetnje gutanja, u 3 bolesnika
neurolepti~ki maligni sindrom (NMS), 2 bolesnika su bila hospitalizirana zbog mo`danog udara, 2 bolesnika imala su
gu{enje bolusom hrane i u 1 bolesnika su bile prisutne smetnje govora. Radna dijagnoza za ve}inu pacijenata bila je
neurolo{ka bolest, tek je kasnije postavljena dijagnoza D-IMD, isklju~enjem primarne neurolo{ke bolesti ili kao pri-
dru`eni poreme}aj osnovnoj neurolo{koj bolesti. Devet pacijenata dijagnosticirano je kao Parkinsonov sindrom, 3 kao
NMS, a 4 kao orolingvalne diskinezije samostalno ili u kombinaciji sa Parkinsonovim sindromom. D-IMD je naj~e{}e
uzrokovan neurolepticima. Time obja{njavamo mali broj hospitaliziranih bolesnika zbog ovog sindroma na Klinici za
neurologiju.
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